CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
degarelixdrug
Likely dose
degarelix 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00738673
NCT00738673Phase 2Completed
CompareCT.gov

An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Ferring Pharmaceuticals·interventional·Posted Aug 20, 2008·Updated Jan 18, 2013

In Brief

A Phase 2 clinical trial evaluating degarelix for Prostate Cancer. Completed, enrolled 37 participants across 15 sites.

Detailed Summary

This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12 months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal treatment in Prostate Cancer patients who experienced PSA-Failure following gonadotropin-releasing hormone (GnRH) agonist treatment. The two cohorts differ in Testosterone levels at inclusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 20, 2008
Enrollment StartJul 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 17.9 years ago

Interventions

degarelixdrug

Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).